Emerging molecular approaches to pain therapy

Journal of Medicinal Chemistry

Volumn 42, Issue 9, 1999, Pages 1481-1500

  Williams, Michael ^a   Kowaluk, Elizabeth A ^b   Arneric, Stephen P ^b  

^a ABBOTT LABORATORIES   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR STIMULATING AGENT; ACETYLSALICYLIC ACID; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; ANALGESIC AGENT; ANESTHETIC AGENT; ANTICONVULSIVE AGENT; ANTIRHEUMATIC AGENT; CANNABINOID; CAPSAICIN; CELECOXIB; CHOLINERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; CYTOKINE; FENTANYL; GLUTAMATE RECEPTOR; GROWTH FACTOR; IBUPROFEN; IMMUNOMODULATING AGENT; INDOMETACIN; KETOROLAC; LEFLUNOMIDE; LOPERAMIDE; MORPHINE; NEUROKININ 1 RECEPTOR ANTAGONIST; NITRIC OXIDE; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE DERIVATIVE; TRAMADOL; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG;

CANCER PAIN; DRUG MECHANISM; DRUG RESEARCH; DRUG SAFETY; GASTROINTESTINAL TOXICITY; HUMAN; INFLAMMATION; NEPHROTOXICITY; NEUROPATHY; NOCICEPTION; PAIN ASSESSMENT; REVIEW;

ADRENERGIC AGONISTS; ANALGESICS, OPIOID; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CHOLINERGIC AGONISTS; CYTOKINES; GABA AGONISTS; GROWTH SUBSTANCES; HUMANS; ION CHANNELS; NITRIC OXIDE; PAIN; RECEPTORS, GLUTAMATE; RECEPTORS, PEPTIDE; RECEPTORS, PURINERGIC;

EID: 0033529014     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm9805034     Document Type: Review

References (189)

1. Prasit, P.; Riendeau, D. Selective cyclooxygenase-2 inhibitors. Annu. Rep. Med. Chem. 1997, 32, 211-220.
2. Vane, J. R.; Bakhle, Y. S.; Botting, R. M. Cyclooxygenases 1 and 2. Annu. Rev. Pharmacol. Toxicol. 1998, 38, 97-120.
3. Morrison, B. W. The analgesic effect of selective COX-2 inhibitors. Presentation at IBC Conference: Novel Targets in the Treatment of Pain, Washington, DC, Oct 6-7, 1997.
4. Cozzens, S. E. Social Control and Multiple Discovery in Science. The Opiate Receptor Case; SUNY Press: Albany, NY, 1989.
5. Carson, J. R. Nonopioid antinociceptive agents structurally related to tramadol. Presentation at IBC Conference: Novel Targets in the Treatment of Pain, Washington, DC, Oct 6-7, 1997.
6. Dray, A.; Urban, L.; Dickenson, A. Pharmacology of chronic pain. Trends Pharmacol. Sci. 1994, 15, 190-197.
7. Lipton, S. Pain mechanisms and management. Br. Med. Bull. 1991, 47 (3)i-iv.
8. Yaksh, T. L. An introductory perspective on the study of nociception and its modulation. In Anesthesia: Biologic Foundations; Yaksh, T. L., Lynch, C., Zapol, W. M., Maze, M., Biebuyck, J. F., Saidman, L. J., Eds.; Lippincott-Raven: Philadelphia, 1998; pp 471-482.
9. Erickson, D. Progress against pain. Start-Up. Windhover's Review of Emerging Medical Ventures 2 1997, April, 8-13.
10. Brownlee, S.; Schrof, J. M. The quality of mercy. U.S. News World Rep. 1997, March 17, 54-67.
11. Breitbart, W.; Rosenfeld, B. D.; Passik; McDonald, M. V.; Thaler, H.; Portenoy, R. K. The undertreatment of pain in ambulatory AIDS patients. Pain 1996, 65, 243-249.
12. Cleeland, C. S. Recommendations for pain management. JAMA 1998, 279, 1914-1915.
13. Zenz, M.; Willweber-Strumpf, A. Opiophobia and cancer pain in Europe. Lancet 1993, 341, 1075-1082.
14. Bernabei, R.; Gambassi, G.; Lapane, K.; Landi, F.; Gatsonis, C.; Dunlop, R.; Lipsitz, L.; Steel, K.; Mor, V. Management of pain in elderly patients with cancer. JAMA 1998, 279, 1877-1882.
15. Kaplan, H. I.; Sadock, B. J.; Grebb, J.A. Chronic Pain. Kaplan and Sadock's Synopsis of Psychiatry. Behavioral Sciences/Clinical Psychiatry, 7th ed.; Williams and Wilkins: Baltimore, 1994; pp 764-765.
16. Woolf, C. J. An overview of the mechanisms of hyperalgesia. Pulm. Pharmacol. 1995, 8, 161-167.
17. Dray, A.; Urban, L. New pharmacological strategies for pain relief. Annu. Rev. Pharmacol. Toxicol. 1996, 36, 253-280.
18. Woolf, C. J. Molecular signals responsible for the reorganization of the synaptic circuitry of the dorsal horn after peripheral nerve injury: the mechanisms of tactile allodynia. Prog. Pain Res. Manag. 1997, 9, 171-200.
19. Brennan, M. B. The molecular roots of pain. Chem. Eng. News. 1997, December 15, 48-51.
20. Levine, J. D. New directions in pain research: molecules to maladies. Neuron 1998, 20, 649-654.
21. Campbell, W. I.; Kendrick, R. W. Pre-emptive analgesia using local anaesthesia: a study in bilaterally symmetrical surgery. Br. J. Anaesth. 1997, 79, 657-659.
22. Fukunaga, A. F. Purines in anesthesia. In Purinergic Approaches in Experimental Therapeutics; Jacobson, K. A., Jarvis, M. F., Eds.; Wiley-Liss: New York, 1997; pp 471-490.
23. Flacke, J. W.; Bloor, B. C.; Flacke, W. E.; Wong, D.; Dazza, S.; Stead, S. W.; Laks, H. Reduced narcotic requirement by clonidine with improved hemodynamic and adrenergic stability in patients undergoing coronary bypass surgery. Anesthesiology 1987, 67, 11-19.
24. Meyer, R. A.; Campbell, J. N.; Raja, S. N. Peripheral neural mechanisms of nociception. In Textbook of Pain, 3rd ed.; Wall, P. D., Melzack, R., Eds.; Churchill-Livingstone: Edinburgh, 1994; pp 13-44.
25. Millan, M. J. The role of descending noradrenergic and serotoninergic pathways in the modulation of nociception: focus on receptor multiplicity. In The Pharmacology of Pain. Handbook Exp. Pharmacol.; Dickenson, A. H., Besson, J.-M., Eds.; Springer Verlag: Berlin, 1997; pp 385-446.
26. Gear, R. W.; Miaskowski, C.; Gordon, N. C.; Paul, S. M.; Heller, P. H.; Levine, J. D. κ-opioids produce significantly greater analgesia in women than in men. Nature Med. 1996, 2, 1248-1250.
27. Bartok, R. E.; Croft, R. M. Sex differences in opioid antinociception. J. Pharmacol. Exp. Ther. 1997, 282, 769-778.
28. Levine, J.; Taiwo, Y. Inflammatory pain. In Textbook of Pain, 3rd ed.; Wall, P. D., Melzack, R., Eds.; Churchill-Livingstone: Edinburgh, 1994; pp 45-56.
29. + current in nociceptors. Proc. Natl. Acad. Sci. U.S.A. 1996, 93, 1108-1112.
30. + channel specific for sensory neurons. J. Biol. Chem. 1997, 272, 20975-20978.
31. Caterina, M. J.; Schumacher, M.; Tominaga, M.; Rosen, T. A.; Levine, J. D.; Julius, D. The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature 1997, 389, 816-824.
32. 2 receptor. Br. J. Pharmacol. 1997, 121, 1445-1453.
33. Neumann, S.; Doubell, T. P.; Leslie, T.; Woolf, C. J. Inflammatory pain hypersensitivity mediated by phenotypic switch in myelinated primary sensory neurons. Nature 1996, 384, 360-364.
34. Dickenson, A H. A cure for wind-up: NMDA receptor antagonists as potential analgesics. Trends Pharmacol. Sci. 1990, 11, 307-309.
35. Dickenson, A. Mechanisms of central hypersensitivity: excitatory amino acid mechanisms and their control. In The Pharmacology of Pain. Handbook Exp. Pharmacol; Dickenson, A. H., Besson, J.-M., Eds.; Springer Verlag: Berlin, 1997; pp 167-210.
36. Cronstein, B. N.; Weissman, G. Targets for antiinflammatory drugs. Annu. Rev. Pharmacol. Toxicol. 1995, 35, 449-462.
37. Breitbart, W. Pharmacotherapy of pain in AIDS. In A Clinical Guide to AIDS and HIV; Wormser, G. P., Ed.; Lippincott-Raven: Philadelphia, 1996; pp 359-365.
38. Sommer, C. L.; Myers, R. R. Pain in acquired immune deficiency syndrome. In Anesthesia: Biologic Foundations; Yaksh, T. L., Lynch, C., Zapol, W. M., Maze, M., Biebuyck, J. F., Saidman, L. J., Eds.; Lippincott-Raven: Philadelphia, 1998; pp 829-839.
39. Mayer, E. A.; Gebhart, G. R. Basic and clinical aspects of visceral hyperalgesia. Gastroenterology 1994, 107, 271-293.
40. Bueno, L.; Fioramonti, J.; Delvaux, M.; Frexinos, J. Mediators and pharmacology of visceral sensitivity, from basic to clinical investigations. Gastroenterology 1997, 112, 1714-1743.
41. Malik, R. A.; Calcutt, N. A. Diabetic neuropathy. In Anesthesia: Biologic Foundations; Yaksh, T. L., Lynch, C., Zapol, W. M., Maze, M., Biebuyck, J. F., Saidman, L. J., Eds.; Lippincott-Raven: Philadelphia, 1998; pp 869-877.
42. Kopp, E.; Ghosh, S. Inhibition of NFκB by sodium salicyate and aspirin. Science 1994, 265, 286-290.
43. Herschman, H. R. Prostglandin synthase 2. Biochim. Biophys. Acta 1996, 1299, 125-140.
44. Kester, M.; Coroneos, E.; Thomas, P. J.; Dunn, M. J. Endothelin Stimulates Prostaglandin Endoperoxide Synthase-2 mRNA Expression and Protein Synthesis through a Tyrosine Kinase-signaling Pathway in Rat Mesangial Cells. J. Biol. Chem. 1994, 269, 22574-22580.
45. Yamagata, K.; Andreasson, K. I.; Kaufman, W. E.; Barnes, C. A.; Worley, P. F. Expression of a mitogen-inducible cyclooxygenase in brain neurons: regulation by synaptic activity and glucocorticoids. Neuron 1993, 11, 371-386.
46. Kaufmann, W. E.; Worley, P. F.; Pegg, J.; Bremer, M.; Isakson, P. COX-2 a synaptically induced enzyme is expressed by excitatory neurons at postsynaptic sites in cerebral cortex. Proc. Natl. Acad. Sci. U.S.A. 1996, 93, 2317-2321.
47. Pritchard, K. A., Jr.; O'Banion, M. K.; Miano, J. M.; Vlasic, N.; Bhatia U. G.; Young, D. A.; Stemerman, M. B. Induction of Cyclooxygenase-2 in Rat Vascular Smooth Muscle Cells in Vitro and in Vivo. J. Biol. Chem. 1994, 269, 8504-8509.
48. 2. Proc. Natl. Acad. Sci. U.S.A. 1997, 94, 6500-6505.
49. Thun, M. J.; Namboordiri, M. M.; Calle, E. E.; Flanders, W. D.; Heath, C. W. Aspirin use and risk of fatal cancer. Cancer Res. 1996, 53, 1322-1327.
50. Kargman, S. L.; O'Neill, G. P.; Vickers, P. J.; Evans, J. F.; Mancini, J. A.; Jothy, S. Expression of Prostaglandin G/H Synthase-1 and -2 Protein in Human Colon Cancer. Cancer Res. 1995, 55, 2556-2559.
51. delta716 knockout mice by inhibition of cyclooxygenase-2 (COX-2.) Cell 1996, 87, 803-809.
52. Kalgutkar, A. S.; Crews, B. C.; Rowlinson, S. W.; Garner, C.; Seibert, K.; Marnett, L. J. Aspirin-like molecules that covalently inactivate cyclooxygenase-2. Science 1998, 280, 1268-1270.
53. Parrett, M. L.; Harris, R. E.; Jparder, F. S.; Ross, M. S.; Clausen, K. P.; Robertson, F. M. Cyclooxygenase-2 gene expression in human breast cancer. Int. J. Oncol. 1997, 10, 503-507.
54. Brietner, J. C. S.; Gau, B. A.; Welsh, K A.; Plassman, B. L.; McDonald, W. M.; Helmas, M. J.; Anthony, J. C. Inverse association of antiinflammatory treatments and Alzheimer's diseases. Neurology 1994, 44, 227-232.
55. Rogers, J.; Kirby, L. C.; Hempelman, S. R.; Berry, D. L.; McGeer, P. L.; Kaszniak, A. W.; Zalinski, J.; Cofield, M.; Mansukhani, L.; Wilson, P.; Kogan, F. Clinical trial of indomethacin in Alzheimer's disease. Neurology 1993, 43, 1609-1611.
56. Brietner, H. S. The role of antiinflammatory drugs in the prevention and treatment of Alzheimer's disease. Annu. Rev. Med. 1996, 47, 401-411.
57. Kalgutkar, A. S.; Crews, B. C.; Rowlinson, S. W.; Garner, C.; Seibert, K.; Marnett, L. J. Aspirin-like molecules that covalently inactivate cyclooxygenase-2. Science 1998, 280, 1268-1270.
58. Clissold, S. P. Paracetamol and phenacetin. Drugs 1988, Suppl. 4, 46-59.
59. Ossipov, M. H.; Malan, T. P., Jr.; Lai, J.; Porreca, F. Opioid pharmacology of acute and chronic pain. In The Pharmacology of Pain. Handbook Exp. Pharmacol; Dickenson, A. H., Besson, J.-M., Eds.; Springer Verlag: Berlin, 1997; pp 306-333.
60. Dhawan, B. N.; Cesselin, F.; Raghubir, R.; Reisine, T.; Bradley, P. B.; Hamon, M. International classification of opioid receptors. Pharmacol. Rev. 1996, 48, 567-583.
61. Reinscheid, R. K.; Nothacker, H.-P.; Bourson, A.; Ardati, A.; Henningsen, R. A.; Bunzow, R.; Grandy, D. K.; Langen, H.; Monsma, F. J.; Civelli, O. Orphanin FQ: a neuropeptide that activates an opioid-like G-protein coupled receptor. Science 1995, 270, 792-794.
62. Henderson, G.; McKnight, A. T. The orphan opioid receptor and its endogenous ligand - nociceptin/ orphanin FQ. Trends Pharmacol. Sci. 1997, 18, 293-300.
63. Stein, C. The control of pain in peripheral tissue by opioids. NEJM 1995, 332, 1685-1690.
64. Sharp, B.; Yaksh T. Pain killers of the immune system. Nature Med. 1997, 3, 831-832.
65. Singhal, P. C.; Sharma, P.; Kapasi, A.; Reddy, A.; Franki, N.; Gibbons, T. Morphine enhances macrophage apoptosis. J. Immunol. 1998, 160, 1886-1893.
66. Levine, J. D.; Fields, H. L.; Basbaum, A. I. Peptides and the primary afferent nociceptor. J. Neurosci. 1993, 13, 2273-2286.
67. Machelska, H.; Cabot, P. J.; Mousa, S. A.; Zhang, Q.; Stein, C. Pain control in inflammation governed by selectins. Nature Med. 1998, 4, 1425-1428.
68. Schafer, M.; Mousa, S. A.; Zhang, Q.; Carter, L.; Stein, C. Expression of corticotrophin-releasing factor in inflamed tissue is required for intrinsic peripheral opioid analgesia. Proc. Natl. Acad. Sci. U.S.A. 1996, 93, 6096-6100.
69. Wilson, J. L.; Walker, J. S.; Anton, J. S.; Perry M. A. Intracellular adhesion molecule-1 expression in adjuvant arthritis: inhibition by kappa-opioid agonists but not by NSAID. J. Rheum. 1998, 25, 499-505.
70. Porreca, F.; Lai, J.; Malan, T. P., Jr. Can inflammation relieve pain? Nature Med. 1998, 4, 1359-1360.
71. Levi-Montalcini, R.; Skaper, S. D.; Toso, R.D.; Petrelli, L.; Leon, A. Nerve growth factor: from neurotrophin to neurokine. Trends Neurosci. 1996, 19, 514-520.
72. Savage, S. R. Addiction in the treatment of pain: significance, recognition and management. J. Pain Symptom. Manage. 1993, 8, 265-278.
73. Cherney, N. I. Opioid analgesics. Comparative features and prescribing guidelines. Drugs 1996, 51, 713-717.
74. Barber, A.; Bartoszyk, G. D.; Bender, H. M.; Gottschlich, R.; Greiner, H. E.; Harting, J.; Mauler, F.; Minck, K. O.; Murray, R. D.; Simon, M. A. Pharmacological profile of the novel, peripherally selective kappa-opioid receptor agonist, EMD 61753. Br. J. Pharmacol. 1994, 113, 1317-1327.
75. Binder, W.; Walker, J. S. Effect of the peripherally selective kappa-opioid agonist, asimadoline, on adjuvant arthritis. Br. J. Pharmacol. 1998, 124, 647-654.
76. Pozzi, O.; Angelica, O.; Petrone, G.; Petrillo, P.; Manzoni, C.; Parolaro D.; Clarke, G. D.; Visentin, L.; Farina, C.; Scheideler, M. A.; Dondio, G. SB 235863, a new non peptidic delta opioid receptor agonist with antihyperalgesic activity. Soc. Neurosci. Abstr. 1998, 24, 352.16.
77. Portenoy, R. K Nontraditional analgesics in the management of cancer pain. In Pain 1996-An Updated Review; Campbell, J.N., Ed.;, MSP Press: Seattle, WA, 1996; pp 559-566.
78. Yaksh, T. L. Antidepressants as analgesics. In Anesthesia: Biologic Foundations; Yaksh, T. L., Lynch, C., Zapol, W. M., Maze, M., Biebuyck, J. F., Saidman, L. J., Eds.; Lippincott-Raven: Philadelphia, 1998; pp 987-997.
79. th Annual Meeting, San Diego, CA, November 1998; 811.
80. Kayser, V.; Desmeules, J.; Guilbaud, G. Systemic clonidine differentially modulates the abnormal reactions to mechanical and thermal stimuli in rats with peripheral mononeuropathy. Pain 1995, 60, 275-285.
81. Fields, H. L.; Rowbotham, M. C.; Devor, M. Excitability blockers: anticonvulsants and low concentration local anesthetics in the treatment of chronic pain. In The Pharmacology of Pain. Handbook Exp. Pharmacol.; Dickenson, A. H., Besson, J.-M., Eds.; Springer Verlag: Berlin, 1997; pp 93-116.
82. Gee, N. S.; Brown, J. P.; Dissanayake, V. U. K.; Offord, J.; Thurlow, R.; Woodruff, G. N. The novel anticonvulsant drug, gabapentin (Neurontin), binds to the α2δ subunit of a calcium channel. J. Biol. Chem. 1996, 271, 5768-5776.
83. Bryans, J. S.; Davies, N.; Gee, N. S.; Dissanayake, V. U. K.; Ratcliffe, G. S.; Horwell, D. C.; Kneen, C. O.; Morrell, A. I.; Oles, R. J.; O'Toole, J. C.; Perkins, G. M.; Singh, L.; Suman-Chaunhan, N.; O'Neill, J. A. Identification of novel ligands for the gabapentin site of the α2δ subunit of a calcium channel and their evaluation as anticonvulsant agents. J. Med. Chem. 1998, 41, 1838-1845.
84. Khan, O. A. Gabapentin relieves trigeminal neuralgia in multiple sclerosis patients. Neurology 1998, 51, 611-614.
85. Giradina, W. J.; Decker, M. W.; Porsolt, R. D.; Roux, S.; Collins, S. D.; Kim, D. J. B.; Bannon, A. W. An evaluation of the GABA uptake blocker tiagabine HCl in animal models of neuropathic and nociceptive pain. Drug Dev. Res. 1998, 44, 106-113.
86. Chaplan, S. R.; Calcutt, N. A.; Scott, B. P.; Zeitlin, A.; Yaksh, T. L. Stereospecific effects of mexiletine in experimental allodynia in the rat. Abstract presented at the IBC Meeting Novel Targets in the Treatment of Pain, Washington, DC, Oct 6-7, 1997.
87. Lan, N. C.; Gee, K. W. Epalons as promising therapeutic agents. Drug News Perspect. 1997, 10, 604-611.
88. Zipkin, I. Big Enbrel hit for Immunex. BioCentury Extra 1997, 5 (83), 1-2
89. Kristensen, J. D.; Svensson, B.; Gordh, T. The NMDA receptor antagonist CPP abolishes neurogenic wind-up pain after intrathecal administration in humans. Pain 1992, 51, 249-253.
90. Lees, K. R. Cerestat and other NMDA receptor antagonists in ischemic stroke. Neurology 1997, 49, S66-S69.
91. Eisenberg, E.; LaCross, S.; Strassman, A. M. The clinically tested N-methyl-D-aspartate receptor antagonist memantine blocks and reverses thermal hyperalgesia in a rat model of painful mononeuropathy. Neurosci. Lett. 1995, 187, 17-20.
92. Stoof, J. C.; Booij, J.; Drukarch, B. Amantidine as N-methyl-D-aspartic acid receptor antagonist: new possibilities for therapeutic applications? Clin. Neurol. Neurosurg. 1992, 94, S4-S6.
93. Eisenberg, E.; Pud, D. Can patients with chronic neuropathic pain be cured by acute administration of the NMDA receptor antagonist amantidine? Pain 1998, 74, 337-339.
94. Pud, D.; Eisenberg, E.; Spitzer, A.; Adler, R.; Fried, G.; Yamistsky, D. The NMDA receptor antagonist amantidine reduces surgical neuropathic pain in cancer patients: a double blind, randomized, placebo controlled trial. Pain 1998, 75, 349-354.
95. Linders, J. T. M. CNS-5161. Curr. Opin. CPNS Investigational Drugs 1999, 1, 167-170.
96. Bleakman, D.; Helton, D. R.; Lodge, D.; Iyengar, S.; Ornstein, P. L. Pharmacological agents. WO 9845270-A, 1998.
97. Vaught, J. L., Pelley, K., Costa, L. G., Setler, P., Enna, S. J. A comparison of the antinociceptive responses to the GABA-receptor agonists THIP and baclofen. Neuropharmacology 1985, 24, 211-216.
98. Levy, R. A.; Proudfit, H. K. The analgesic action of baclofen [β-(4-chlorophenyl)-γ-aminobutyric acid]. J. Pharmacol. Exp. Ther. 1977, 202, 437-455.
99. Kjaer, M.; Neilsen, H. The analgesic effect of the GABA agonist THIP in patients with chronic pain of malignant origin. Br. J. Clin. Pharmacol. 1983, 16, 477-485.
100. Hammond, D. L. Inhibitory neurotransmitters and nociception: role of GABA and glycine. In The Pharmacology of Pain. Handbook Exp. Pharmacol.; Dickenson, A. H., Besson, J.-M., Eds.; Springer Verlag: Berlin, 1997; pp 361-383.
101. Gotti, C.; Fornasari, D.; Clementi, F. Human neuronal nicotinic receptors. Prog. Neurobiol. 1997, 53, 199-237.
102. Holladay, M.; Dart, M.; Lynch, J. Neuronal nicotinic acetylcholine receptors as targets for drug discovery. J. Med. Chem. 1997, 40, 4169-4194.
103. Badio, B.; Garraffo, H. M.; Spande, T. F.; Daly, J. W. Epibatidine: discovery and definition as a potent analgesic and nicotinic agonist. Med. Chem. Res. 1994, 4, 440-448.
104. Bannon, A. W.; Decker, M. W.; Holladay, M. W.; Curzon, P.; Donnelly-Roberts, D. D.; Puttfarcken, P. S.; Bitner, R. S.; Diaz, A.; Dickenson, A. H.; Porsolt, R. D.; Williams, M.; Arneric, S. P. Broad spectrum, nonopioid analgesic activity by selective modulation of neuronal nicotinic acetylcholine receptors. Science 1998, 279, 77-80.
105. Ghelardini, G.; Galeotti, N.; Barlocco, D.; Bartolini, A. Antinociceptive profile of a new nicotinic agonist DBO-83. Drug Dev. Res. 1997, 41, 251-258.
106. Ghelardini, G.; Galeotti, N.; Gualtieri, F.; Bellucci, C.; Manetti, D.; Borea, P. A.; Bartolini, A. Antinociceptive property of the nicotinic agonist AG-4 in rodents. Drug Dev. Res. 1997, 41, 1-9.
107. Shannon, H. E.; Sheardown, M. J.; Bymaster, F. P.; Calligaro, D. A.; Delapp, N. W.; Gidda, J.; Mitch, C. H.; Sawyer, B. D.; Stengl, P. W.; Ward, J. S.; Wong, D. T.; Oleson, P. H.; Suzdak, P. D.; Sauerberg, P.; Swedberg, M. D. B. Pharmacology of butylthio [2.2.2.] (LY297802/NNC11-1053): a novel analgesic with mixed muscarinic receptor agonist and antagonist activity. J. Pharmacol. Exp. Ther. 1997, 281: 884-894.
108. Sauerberg, P.; Oleson, P. H.; Sheardown, M. J.; Rimvall, K.; Thorgesen, H.; Shannon, H. E.; Sawyer, B. D.; Ward, J. S.; Bymaster, F. P.; Delapp, N. W.; Calligaro, D. O.; Swedberg, M. D. B. Conformationally constrained analogues of the muscarinic agonist 3-(4(methylthio)-1,2,5,-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyridine. Synthesis, receptor affinity, and antinociceptive activity. J. Med. Chem. 1998, 41, 109-118.
109. Ghelardini, G.; Galeotti, N.; Fantetti, L.; Gualtieri, F.; Dei, S.; Scapecchi, S.; Bartolini, A. Central muscarinic antinociception induced by ET-142 and SS-20 in rodents. Drug Dev. Res. 1997, 42, 26-34.
110. Ghelardini, G.; Galeotti, N.; Gualtieri, F.; Bellucci, C.; Manetti, D.; Giotti, A.; Malmberg-Aiello, G.; Galli, A.; Bartolini, A. Antinociceptive profile of 3-α-tropanyl-(2-Cl)-acid phenoxybutyrate (SM-21): a novel analgesic with a presynaptic cholinergic mechanism of action. J. Pharmacol. Exp. Ther. 1997, 282, 430-439.
111. Burnstock, G. A unifying purinergic hypothesis for the initiation of pain. Lancet 1996, 347, 1604-1605.
112. Burnstock, G.; Wood, J. N. Purinergic receptors: their role in nociception and primary afferent neurotransmission. Curr. Opin. Neurobiol. 1996 6, 526-532.
113. Sawynok, J. Purines in pain management. Curr. Opin. CPNS Investigational Drugs 1999, 1, 27-38.
114. Taiwo, Y. O.; Levine, J. D. Direct cutaneous hyperalgesia induced by adenosine. Neuroscience 1990, 38, 757-762.
115. Segerdahl, M.; Sollevi, A. Adenosine and pain relief: a clinical overview. Drug. Dev. Res. 1998, 45, 151-158.
116. 1-selective adenosine agonist abolishes allodynia elicited by vibration and touch after intrathecal injection. Anesth. Analg. 1995, 80, 844-847.
117. Bellfrage, M.; Sollevi, A.; Segerdahl, M.; Sjolund, K. F.; Hansson, P. Systemic adenosine infusion alleviates spontaneous and stimulus evoked pain in patients with peripheral neuropathic pain. Anesth. Analg. 1995, 81 713-717.
118. Sumida, T.; Smith, M. A.; Maehara, Y.; Collins, J. G.; Kitahara, L. M. Spinal R-phenyl-isopropyl adenosine inhibits spinal dorsal horn neurons responding to noxious heat stimulation in the presence and absence of sensitization. Pain 1998, 74, 307-313.
119. 3 receptor activation produces nociceptive behavior and edema by release of histamine and 5-hydroxytryptamine. Eur. J. Pharmacol. 1997, 333, 1-7.
120. 1 receptor-mediated excitation of nociceptive afferents innervating the normal and arthritic knee joint. Br. J. Pharmacol. 1998, 125, 341-346.
121. Segerdahl, M.; Irestedt, L.; Sollevi, A. Antinociceptive effect of perioperative adenosine infusion in abdominal hysterectomy. Acta Anesth. Scand. 1997, 41, 180-185.
122. Wang, B.; Tang, J.; White, P. F.; Foster, A. C..; Grettenberger, H. M.; Kopcho, J..; Wender, R. H. The effects of GP683, an adenosine kinase inhibitor, on the desflurane anesthetic requirement in dogs. Anesth. Analg. 1997, 85, 675-680.
123. Kowaluk, E. A.; Bhagwat, S. S.; Jarvis, M. F. Adenosine kinase inhibitors. Curr. Pharm. Des. 1998, 4, 403-416.
124. Firestein, G. S. Antiinflammatory effects of adenosine kinase inhibitors in acute and chronic inflammation. Drug Dev Res. 1996, 39, 371-376.
125. Cronstein, B. N. Adenosine regulation of neutrophil function and inhibition of inflammation via adenosine receptors. In Purinergic Approaches in Experimental Therapeutics; Jacobson, K. A., Jarvis, M. F., Eds.; Wiley-Liss, New York, 1997; pp 285-299.
126. 2a receptor. Nature 1997, 385, 674-678.
127. Bowler, A. N.; Raven, A.; Olsen, U. B.; Thomsen, C.; Knutsen, L. J. S. Ribose modified N-methoxyadenosine analogues controlling cytokines. Drug Dev. Res. 1998, 43, 26.
128. Driessen, B.; Reimann, W.; Selve, N.; Friderichs, E.; Bultmann, R. Antinociceptive activity of intrathecally administered P2-purinoceptor antagonists in rats. Brain Res. 1994, 666, 182-188.
129. Li, J.; Perl, E. R. ATP modulation of synaptic transmission in the spinal substantia gelatinosa. J. Neurosci. 1995, 15, 3357-3365.
130. Bland-Ward, P. A.; Humphrey, P. P. A. Acute nociception mediated by hindpaw P2X receptor activation in the rat. Br. J. Pharmacol. 1997, 122, 365-371.
131. Bardoni, R;, Goldstein, P.; Lee, J.; Gu, J. G.; MacDermott, A. B. ATP P2X receptors mediate fast synaptic neurotransmission in the dorsal horn of the spinal cord. J. Neurosci. 1997, 17, 5297-5304.
132. 2X purinoceptor expressed by a subset of sensory neurons. Nature 1995, 377, 428-431.
133. 3 receptor subunits can account for ATP-gated currents in sensory neurons. Nature 1995, 377, 432-435.
134. Vulchanova, L.; Arvidsson, U.; Riedl, M.; Wang, J.; Buell, G.; Surprenant, A.; North, R. A.; Elde, R. Differential distribution of two ATP-gated ion channels (P2X receptors) determined by immunocytochemistry. Proc. Natl. Acad. Sci. U.S.A. 1996 93, 8063-8067.
135. 3 receptors in normal and neuropathic rats. Pharmacologist 1997, 39, 56.
136. Gu, J. G.; MacDermott, A. B. Activation of ATP P2X receptors elicits glutamate release from sensory neuron synapses. Nature 1997, 389, 749-753.
137. Manzoni, O. J.; Manabe, T.; Nicoll, R. A. Release of adenosine by activation of NMDA receptors in the hippocampus. Science 1994, 265, 2098-2101.
138. Cook, S. P.; Vulchanova, L.; Hargreavea, K. M.; Elde, R..; McClesky, E. W. Distinct ATP receptors on pain-sensing and stretch-sensing neurons. Nature 1997, 387, 505-508.
139. Jarvis, M. F.; Williams, M. Purinergic mechanisms in nervous system function and disease states. In Psychopharmacology: 4th Generation of Progress; Bloom, F. E., Kupfer, D. J., Eds.; Raven: New York, 1999, CD-ROM.
140. Eisenach, J. C. Analgesic drug classes in the management of clinical pain: α2-agonists. In Anesthesia: Biologic Foundations; Yaksh, T. L., Lynch, C., Zapol, W. M., Maze, M., Biebuyck, J. F., Saidman, L. J., Eds.; Lippincott-Raven: Philadelphia, 1998; pp 935-942.
141. Jaakola, M.-L.; Salonen, M.; Lehtinen, R.; Scheinin, R. The analgesic action of dexmedetomidine - a novel α2-adrenoceptor agonist - in healthy volunteers. Pain 1991, 46, 281-285.
142. 2a - adrenergic receptor via "hit and run" gene targeting reveals the role of this subtype in sedative, analgesic, and anesthetic - sparing responses in vivo. Proc. Natl. Acad. Sci. U.S.A. 1997, 94, 9950-9955.
143. Holthusen, H.; Arndt, J. O. Nitric oxide evokes pain in humans on intracutaneous injection. Neurosci. Lett. 1994, 165, 71-74.
144. Kawabata, A.; Fukuzumi, Y.; Fukushima, Y.; Takagi, H. Antinociceptive effect of 1-arginine on the carrageenin-induced hyperalgesia of the rat: possible involvement of central opioid systems. Eur. J. Pharmacol. 1992, 218, 153-158.
145. Vizzard, M. A.; Erdman, S. L.; DeGroat, W. C. Increased expression of neuronal nitric oxide synthase (NOS) in visceral neurons after nerve injury. J. Neurosci. 1995, 15, 4033-4045.
146. Xu, X.-J.; Wiesenfeld-Hallin, Z. Novel modulators in nociception. In The Pharmacology of Pain. Handbook Exp. Pharmacol.; Dickenson, A. H., Besson, J.-M., Eds.; Springer Verlag: Berlin, 1997; pp 211-234.
147. Huizinga, T. W. J. NCX-4016. Drugs 1998, 1, 228-231.
148. Mills, S. G. Recent advances in neurokinin receptor antagonists. Annu. Rep. Med. Chem. 1997, 32, 51-60.
149. Bozic, C. R.; Lu, B.; Hoken, U. E.; Gerard, C.; Gerard, N. P. Neurogenic amplification of immune complex inflammation. Science 1996, 273, 1722-1725.
150. Birch, P. J. Tachykinins: central and peripheral effects. In The Pharmacology of Pain. Handbook Exp. Pharmacol.; Dickenson, A. H., Besson, J.-M., Eds.; Springer Verlag: Berlin, 1997; pp 115-133.
151. 1 tachykinin receptor antagonist with good oral analgesic activity in chronic pain models. J. Med. Chem. 1998, 41, 3159-3173.
152. Kramer, M. S.; Cutler, N.; Feighner, J.; Shrivasatava, R.; Carman, J.; Sramek, J. J.; Reines, S. A.; Liu, G.; Snavely, D.; Wyatt-Knowles, E.; Hale, J. J.; Mills, S. G.; MacCoss, M.; Swain, C. J.; Harrison, T.; Hill, R. G.; Hefti, F.; Scolnick, E. M.; Cascieri, M. A.; Chicci, G. G.; Sadowaksi, S.; Williams, A. R.; Hewson, L.; Smith, D.; Carlson, E. J.; Hargreaves, R. J.; Rupniak, N. M. J. Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science 1998, 281, 1640-1645.
153. De Felipe, C.; Herrero, J F.; O'Brien, J. A.; Palmer, J. A.; Doyle, C. A.; Smith, A. J. H.; Laird, J. M. A.; Belmomte, C.; Cervero, F.; Hunt, S. P. Altered nociception, analgesia and aggression in mice lacking the receptor for substance P. Nature 1998 392, 394-397.
154. Mantyh, P. W.; Allen, C. J.; Ghilardi, J. R.; Rogers, S. D.; Mantyh, C. R.; Liu, H.; Basbaum, A. I.; Vigna, S. R.; Maggio, J. E. Rapid endocytosis of G protein-coupled receptor: substance P-evoked internalization of its receptor in the rat striatum in vivo. Proc. Natl. Acad. Sci. U.S.A. 1995, 92, 2622-2626.
155. Rang, H. P.; Bevan, S.; Dray, A. Chemical activation of nociceptive peripheral neurons. Br. Med. Bull. 1991, 47, 534-548.
156. 8BK and HOE 140, in two models of persistent hyperalgesia in the rat. Pain 1993, 53, 191-197.
157. Verge, V. M. K.; Wisenfeld-Hallin, Z.; Hokfelt, T. Cholecystokinin in mammalian primary sensory neurons nad spinal cord: in situ hybridization studies in rat and monkey. Eur. J. Neurosci. 1993, 5, 240-250.
158. Cesare, P.; McNaughton, P. Peripheral pain mechanisms. Curr. Opin. Neurobiol. 1997, 7, 493-499.
159. + channels as targets for anticonvulsant, analgesic and neuroprotective drugs. Curr. Pharm. Des. 1998, 2, 375-388.
160. Nobbs, M. S.; Rodgers, S. J. Preparation of (R)-2,4-diamino-5-(2,3-dichlorophenyl)-6-fluoromethyl pyrimidine as a drug. WO 9709317 A2, 1997.
161. Miller, A. A.; Nobbs, M. S.; Hyde, R. M.; Leach, M. J. Preparation and formulation of phenylpyrimidines for treating central nervous system disorders. EP 372934 A2, 1997.
162. Jack, D. B. Wider use of cannabinoids? Drug News Perspect. 1997, 10, 440-442.
163. Calignano, A.; La Rena, G.; Giuffrida, A.; Piomelli, D. Control of pain initiation by endogenous cannabinoids. Nature 1998, 394, 277-281.
164. Richardson, J. D.; Aaanonsen, L.; Hargreaves, K. M. Hypoactivity of the spinal cannabinoid system results in NMDA-dependent hyperalgesia. J. Neurosci. 1998, 18, 451-457.
165. McMahon, S. B.; Bennett, D. L. H. Growth factors and pain. In The Pharmacology of Pain. Handbook Exp. Pharmacol. Dickenson, A. H., Besson, J.-M., Eds.; Springer Verlag: Berlin, 1997; pp 135-165.
166. Lewin, G. R.; Ruff, A.; Mendell, L. M. Peripheral and central mechanisms of NGF-induced hyperalgesia. Eur. J. Neurosci. 1994, 6, 1903-1912.
167. Bergmann, I.; Priestly, J. V.; McMahon, S. B.; Brocker, E. B.; Toyka, K. V.; Koltzenberg, M. Analysis of cutaneous sensory neurons in transgenic mice lacking the low affinity neurotrophin receptor p75. Eur. J. Neurosci. 1897, 9, 18-28.
168. Ma, Q. P.; Woolf, C. J. Progressive tactile hypersensitivity: an inflammation-induced incremental increase in the excitability of the spinal cord. Pain 1996, 67, 97-106.
169. Dyck, P. J.; Peroutka, S.; Rask, C.; Burton, E.; Baker, M. K.; Lehman, K. A.; Gillen, D. A.; Hokanson, J. L.; O'Brien, P. C. Intradermal recombinant human nerve growth factor induces pressure allodynia and lowered heat pain threshold in humans. Neurology 1997, 48, 501-505.
170. Ma, Q. P.; Woolf, C. J. The progressive tactile hyperalgesia induced by peripheral inflammation is nerve growth factor dependent. NeuroReport 1997, 8, 807-810.
171. Bevan, S.; Winter, J. Nerve growth factor (NGF) differentially regulates the chemosensitivity of adult cultured sensory neurons. J. Neurosci. 1995, 15, 4918-4926.
172. Aguayo, L. G.; White, G. Effects of nerve growth factor on TTX- and capsaicin-sensitivity in adult rat sensory neurones. Brain Res. 1992, 570, 61-67.
173. Szallasi, A. The vanilloid (capsaicin) receptor: receptor types and species differences. Gen. Pharmacol. 1994, 25, 223-243.
174. Szallasi, A. Perspectives on vanilloids in clinical practice. Drug News Perspect. 1997, 10, 522-527.
175. Perkins, M. N.; Campbell, E. A. Capsazepine reversal of the analgesic action of capsaicin in vivo. Br. J. Pharmacol. 1992, 107, 329-333.
176. Dray, A.; Bettaney, J.; Rueff, A.; Walpole, C.; Wrigglesworth, R. NE-19550 and NE-21610, antinociceptive capsaicin analogues: studies on nociceptive fibres of the neonatal rat tail in vitro. Eur. J. Pharmacol. 1990, 181, 289-293.
177. Badger, A. M.; Lee, J. C. Advances in antiarthritic therapeutics. Drug Discuss. Today 1997, 2, 427-434.
178. Cunha, F. Q.; Poole, S.; Lorenzetti, B. B.; Ferreira, S. H. The pivotal role of tumor necrosis factor a in the development of inflammatory hyperalgesia. Br. J. Pharmacol. 1992, 107, 660-664.
179. Perregaux, D.; Gabel, C. A. Interleukin 1-β maturation and release in response to ATP and nigericin. J. Biol. Chem. 1994, 2669, 15195-15203.
180. 7 receptor: a pivotal role in inflammation and immunomodulation. Drug Dev. Res. 1998, 45, 207-213.
181. Chapleo, C. P. Controlling pain in the 21st century. Drug News Perspect. 1997, 10, 443-447.
182. Rasmussen, H. J.; McCann, P. P. Matrix metalloproteinase inhibition as a novel anticancer strategy: a review with special focus on batimastat and marimastat. Pharmacol. Ther. 1997, 75, 69-75.
183. Baldwin, A. S. The NF-κB and IκB proteins: New discoveries and insights. Annu. Rev. Immunol. 1996, 14, 649-681.
184. Parnham, M. J. Inflammation: from molecular biology to clinic. Drug News Perspect. 1998, 11, 44-51.
185. Sora, I.; Takahashi, N.; Funada, M.; Ujike, H.; Revay, R. S.; Donovan, D. M.; Miner, L. L.; Uhl, G. R. Opioid Receptor Knockout Mice Define Mu Receptor Roles in Endogenous Nociceptive Responses and Morphine-Induced Analgesia. Proc. Natl. Acad. Sci. U.S.A. 1997, 94, 1544-1549.
186. Matthies, H. W. D.; Maldonado, R.; Simonin, F.; Valverde, O.; Slowe, S.; Kitchen, I.; Befort, K.; Dierich, A.; Lemeur, M.; Dolle, P.; Tzavara, E.; Hanoune, J.; Roques, B. P.; Kieffer, B. L. Loss of Morphine-Induced analgesia, Reward Effect and Withdrawal Symptoms in Mice Lacking the Mu-Opioid-Receptor Gene. Nature 1996, 383, 819-823.
187. Murata, T.; Ushikubi, F.; Matsuoka, T.; Hirata, M.; Yamasaki, A.; Sugimoto, Y.; Ichikawa, A.; Aze, Y.; Tanaka, T.; Yoshida, N.; Ueno, A.; Oh-Ishi, S.; Narumiya, S. Altered pain perception and inflammatory response in mice lacking prostacyclin receptor. Nature 1997, 388, 678-682.
188. Malmberg, A. B.; Chen, C.; Tonegawa, S.; Busbaum, A. I. Preserved acute pain and reduced neuropathic pain in mice lacking PKCγ. Science 1997, 278, 279-283.
189. Tjolsen, A.; Hole, K. Animal models of analgesia. In The Pharmacology of Pain. Handbook Exp. Pharmacol.; Dickenson, A. H., Besson, J.-M., Eds.; Springer Verlag: Berlin, 1997; pp 1-20.